Biodexa Pharmaceuticals Plc
NASDAQ: BDRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stephen Anthony Stamp
- Employees
- 13
- Headquarters
- Cardiff, United Kingdom
- IPO year
- 2015
- Market cap
- $1.9M
- Website
- https://www.biodexapharma.com
Loading BDRX…
Loading profile data…Frequently asked questions about BDRX
What does Biodexa Pharmaceuticals Plc (BDRX) do?
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are foc...
Where does BDRX trade?
Biodexa Pharmaceuticals Plc (BDRX) trades on the NASDAQ Capital Market.
What sector is BDRX in?
Biodexa Pharmaceuticals Plc (BDRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Biodexa Pharmaceuticals Plc?
Stephen Anthony Stamp is the chief executive officer of Biodexa Pharmaceuticals Plc (BDRX).
Where is Biodexa Pharmaceuticals Plc headquartered?
Biodexa Pharmaceuticals Plc is headquartered in United Kingdom.
Does BDRX pay a dividend?
Biodexa Pharmaceuticals Plc (BDRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BDRX go public?
Biodexa Pharmaceuticals Plc (BDRX) completed its initial public offering in 2015.
Is BDRX an ADR?
Yes — BDRX is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Biodexa Pharmaceuticals Plc reporting and dividends follow the underlying issuer.